SYGNIS Pharma AG Release: GBC Research Reiterates “BUY” Recommendation For SYGNIS Shares With Price Target Of €4.05
Madrid, Spain and Heidelberg, Germany, November 19th, 2014 – GBC Research, a German independent research house focusing on listed small and midcap companies, has published a research update on the DNA amplification and sequencing tools company SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard segment of the German Stock Exchange).
In its current analysis, GBC reports on the new strategy of SYGNIS, whose main focus, apart from the further development of the product portfolio, is on the commercialization of proprietary products. Especially the marketing of PrimPol is representative for the new commercialization strategy of SYGNIS AG, aiming at reducing dependency on strategic partners. As part of this strategy, the proprietary commercialization of the first product line TruePrime™ based on PrimPol is planned already for the beginning of 2015. The resolved rights offer aiming for gross proceeds of up to €4.95 million should give the company the financial basis to fund the product pipeline and the proprietary SYGNIS kits.
GBC believes that the demand for NGS technologies will be driven by dynamic growth rates. The research institute MarketsandMarkets estimates the global NGS market volume, today worth $2.5 billion, to reach $8.7 billion by 2020. The expansion of the product portfolio and the relatively short time required for the development of SYGNIS’ products (usually less than two years) should allow a successful participation in market growth.
Based on an expected increase in sales, GBC estimates revenues for the fiscal years 2015 and 2016 with €2.06 million and €5.45 million respectively. GBC highlights that SYGNIS is well positioned with its product portfolio in order to participate in the high growth rates of the NGS market.
GBC has calculated a fair value per share of €4.05 based on the updated DCF model and thus reiterates the BUY recommendation with a current share price of €2.64. Including the first product launches by QIAGEN based on SYGNIS’ proprietary SensiPhi® technology and the successful completion of the funding of the new business model, the GBC analysis calculates a company value of €53.4 million.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.es
About SYGNIS AG: www.sygnis.com
Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi®, licensed to an industry leading partner and is currently developing its own TruePrime™ product line based on its proprietary PrimPol technology for use in the fast growing field of Next Generation Sequencing. The first product for single cell DNA amplification is expected to be launched in January 2015.
###
Disclaimer
This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###
Help employers find you! Check out all the jobs and post your resume.
In its current analysis, GBC reports on the new strategy of SYGNIS, whose main focus, apart from the further development of the product portfolio, is on the commercialization of proprietary products. Especially the marketing of PrimPol is representative for the new commercialization strategy of SYGNIS AG, aiming at reducing dependency on strategic partners. As part of this strategy, the proprietary commercialization of the first product line TruePrime™ based on PrimPol is planned already for the beginning of 2015. The resolved rights offer aiming for gross proceeds of up to €4.95 million should give the company the financial basis to fund the product pipeline and the proprietary SYGNIS kits.
GBC believes that the demand for NGS technologies will be driven by dynamic growth rates. The research institute MarketsandMarkets estimates the global NGS market volume, today worth $2.5 billion, to reach $8.7 billion by 2020. The expansion of the product portfolio and the relatively short time required for the development of SYGNIS’ products (usually less than two years) should allow a successful participation in market growth.
Based on an expected increase in sales, GBC estimates revenues for the fiscal years 2015 and 2016 with €2.06 million and €5.45 million respectively. GBC highlights that SYGNIS is well positioned with its product portfolio in order to participate in the high growth rates of the NGS market.
GBC has calculated a fair value per share of €4.05 based on the updated DCF model and thus reiterates the BUY recommendation with a current share price of €2.64. Including the first product launches by QIAGEN based on SYGNIS’ proprietary SensiPhi® technology and the successful completion of the funding of the new business model, the GBC analysis calculates a company value of €53.4 million.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.es
About SYGNIS AG: www.sygnis.com
Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi®, licensed to an industry leading partner and is currently developing its own TruePrime™ product line based on its proprietary PrimPol technology for use in the fast growing field of Next Generation Sequencing. The first product for single cell DNA amplification is expected to be launched in January 2015.
###
Disclaimer
This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###
Help employers find you! Check out all the jobs and post your resume.